Disease control in patients with relapsed and/or refractory multiple myeloma: What is the optimal duration of therapy?

Leukemia Research

Volumn 36, Issue SUPPL.1, 2012, Pages

  Ludwig, Heinz ^a   Sonneveld, Peter ^b  

^a Wilhelminenspital   (Austria)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Continuous treatment; Duration of therapy; Long term treatment; Multiple myeloma; Novel agents; Re treatment; Relapsed refractory

Indexed keywords

B CELL ACTIVATING FACTOR; BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; GLUCOCORTICOID; LENALIDOMIDE; LORVOTUZUMAB MERTANSINE; MAPATUMUMAB; MELPHALAN; PANOBINOSTAT; PLACEBO; POMALIDOMIDE; PREDNISONE; PX 171 009; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EFFECTIVENESS; CONSTIPATION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVIDENCE BASED MEDICINE; HEMATOLOGIC DISEASE; HUMAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; LUNG CANCER; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; RELAPSED AND REFRACTORY MULTIPLE MYELOMA; RETREATMENT; SOLID TUMOR; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CALIBRATION; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; MAINTENANCE CHEMOTHERAPY; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; THALIDOMIDE; TIME FACTORS;

EID: 84869994517     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/S0145-2126(12)70006-1     Document Type: Article

References (111)

1. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, Inter-Groupe Francophone du Myélome (IFM), et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006, 108(10):3289-3294.
2. Longo D, Anderson K Plasma cell disorders. Harrison's principles of internal medicine 2004, 656-662. MacGraw-Hill Companies Inc., New York. 16th ed. D. Longo, A. Fauci, D. Kasper, S. Hauser, J. Jameson, J. Loscalzo (Eds.).
3. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006, 132(5):584-593.
4. Prince HM, Schenkel B, Mileshkin L An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007, 48(1):46-55.
5. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, Multiple Myeloma (010) Study Investigators, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357(21):2123-2132.
6. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Multiple Myeloma (009) Study Investigators, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357(21):2133-2142.
7. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352(24):2487-2498.
8. Brenner H, Gondos A, Pulte D Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica 2009, 94(2):270-275.
9. Ludwig H, Bolejack V, Crowley J, Bladé J, Miguel JS, Kyle RA, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010, 28(9):1599-1605.
10. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003, 27(10):909-914.
11. Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity and biological activity. Mayo Clin Proc 2004, 79(7):875-882.
12. Yakoub-Agha I, Mary JY, Hulin C, Doyen C, Marit G, Benboubker L, Intergroupe Francophone du Myélome (IFM), et al. Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. Eur J Haematol 2011, 88(3):249-259.
13. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001, 12(7):991-995.
14. Palumbo A, Giaccone L, Bertola A, Pregno P, Bringhen S, Rus C, et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001, 86(4):399-403.
15. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004, 5(4):318-324.
16. Garderet L, Iacobelli S, Moreau P, Dib M, Caillot D, Niederwiesser D, et al. Bortezomib (Velcade®)-thalidomide-dexamethasone (VTD) is superior to thalidomide-dexamethasone (TD) in patients with multiple myeloma (mm) progressing or relapsing after autologous transplantation. Haematologica (EHA Annual Meeting Abstracts) 2011, 96(Suppl. 2). [Abstract 1008].
17. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, et al. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008, 22(7):1419-1427.
18. Kyriakou C, Thomson K, D'Sa S, Flory A, Hanslip J, Goldstone AH, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005, 129(6):763-770.
19. Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Italian Multiple Myeloma Network, Gruppo Italiano Malattie Ematologicche dell'Adulto, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007, 109(7):2767-2772.
20. Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008, 22(12):2247-2256.
21. Palumbo A, Larocca A, Falco P, Sanpaolo G, Falcone AP, Federico V, et al. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia 2010, 24(5):1037-1042.
22. Offidani M, Corvatta L, Polloni C, Gentili S, Mele A, Rizzi R, et al. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. Ann Hematol 2011, 90(12):1449-1456.
23. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110(10):3557-3560.
24. Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008, 143(4):537-540.
25. Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009, 144(2):169-175.
26. Dimopoulos MA, De Samblanx HM, Roussou MG, Zervas K, Katodritou E, Sargin D, et al. Efficacy of bortezomib plus dexamethasone versus bortezomib monotherapy in patients with relapsed/refractory multiple myeloma: an interim report from an international electronic observational study. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 3027].
27. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007, 25(25):3892-3901.
28. Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, DOXIL-MMY-3001 Study Investigators, et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008, 112(7):1529-1537.
29. Soroka-Wojtaszko M, Walter-Croneck A, Jawniak D, Kozinska J, Charlinski G, Boguradzki P, et al. Evaluation of efficacy and safety of bortezomib, doxorubicin and dexamethasone (pad)regimen in patients with relapsed and refractory multiple myeloma. Haematologica (EHA Annual Meeting Abstracts) 2011, 96(Suppl. 2). [Abstract 0891].
30. Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Korean Multiple Myeloma Working Party (KMMWP), et al. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol 2010, 89(5):475-482.
31. Berenson JR, Yellin O, Cartmell AD, Woliver TBS, Flam MS, Nassir Y, et al. A phase II study of pegylated liposomal doxorubicin (PLD), bortezomib, dexamethasone and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 3044].
32. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006, 108(10):3458-3464.
33. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009, 144(6):895-903.
34. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009, 23(11):2147-2152.
35. Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009, 113(18):4137-4143.
36. Baz R, Walker E, Karam MA, Choueiri TK, Jawde RA, Bruening K, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006, 17(12):1766-1771.
37. Lazaryan A, Baz R, Hussein MA, Elson P, Faiman B, Habecker B, et al. Mature results of MM011: a phase I/II trial of lenalidomide, liposomal doxorubicin, dexamethasone, and vincristine, followed by lenalidomide maintenance (DVd-R) for relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 1967].
38. Reece DE, Masih-Khan E, Khan A, Dean S, Fung S, Anglin P, et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide (Revlimid®) (CPR) for the treatment of patients with relapse and refractory multiple myeloma. Blood (ASH Annual Meeting Abstract) 2010, 116. [Abstract 3055].
39. Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009, 114(4):772-778.
40. Richardson PG, Jagannath S, Jakubowiak AJ, Lonial S, Raje N, Alsina M, et al. Phase II trial of lenalidomide, bortezomib and dexamethasone in patients (pts) with relapsed and relapsed/refractory multiple myeloma (MM): updated efficacy and safety data after >2 years of follow-up. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 3049].
41. Kumar SV, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004, 79(7):867-874.
42. Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, et al. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009, 82(6):426-432.
43. Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007, 67(2):746-755.
44. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99(12):4525-4530.
45. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010, 10(2):155-167.
46. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006, 108(2):618-621.
47. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14(14):4650-4657.
48. Haslett PA, Hanekom WA, Muller G, Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003, 187(6):946-955.
49. Harousseau J-L, Dimopoulos MA, Wang M, Corso A, Chen C, Attal M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010, 95(10):1738-1744.
50. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011, 11(1):38-43.
51. Dimopoulos MA, Palumbo A, Attal M, Beksaç M, Davies FE, Delforge M, European Myeloma Network, et al. Optimizing the use of lenalidomide in relapsed or refracotry multilpe myeloma: consensus statement. Leukemia 2011, 25(5):749-760.
52. Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005, 104(10):2141-2148.
53. Niesvizky R, Flinn IW, Rifkin RM, Gabrail NY, Charu V, Clowney B, et al. Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 619].
54. Mateos M-V, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, et al. Bortezomib, melphalan and prednisone versus bortezomib, thalidomide and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide verusus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomized trial. Lancet Oncol 2010, 11(10):934-941.
55. Palumbo A, Bringhen S, Cavalli M, Ria R, Offidani M, Patriarca F, et al. Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of eldery multiple myeloma patients: updated follow-up and impact of prognostic factors. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 620].
56. Sonneveld P, Schmidt-Wolf I, van der Holt B, el Jarari L, Bertsch U, Salwender J, et al. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 40].
57. Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, Dutch-Belgian Hemato-Oncology Group (HOVON), et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010, 115(6):1113-1120.
58. Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010, 11(11):1086-1095.
59. Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012, 119(1):7-17.
60. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Intergroupe Francophone du Myélome, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM99-06): a randomised trial. Lancet 2007, 370(9594):1209-1218.
61. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008, 112(8):3107-3114.
62. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM01/01 trial. J Clin Oncol 2009, 27(22):3664-3670.
63. Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M, et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 2009, 84(10):657-660.
64. Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 2008, 6(10):755-760.
65. Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymphoma Myeloma 2008, 8(3):140-145.
66. Madan S, Lacy MQ, Dispenzieri A, Gertz MA, Buadi F, Hayman SR, et al. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood 2011, 118(7):1763-1765.
67. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010, 28(33):4976-4984.
68. Dimopoulos M, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010, 116(16):3807-3814.
69. Dimopoulos MA, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 2010, 85(1):1-5.
70. Klein U, Neben K, Hielscher T, Heiss C, Ho AD, Goldschmidt H Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol 2011, 90(4):429-439.
71. REVLIMID® (lenalidomide). Prescribing information, revised October 2010 Accessed October 9, 2012. http://www.revlimid.com/pdf/REVLIMID_PI.pdf.
72. Revlimid. Summary of product characteristics, revised May 2011 Accessed October 9, 2012. http://www.medicines.org.uk/EMC/medicine/19841/SPC/Revlimid/.
73. Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, et al. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005, 74(3):212-216.
74. Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009, 27(34):5713-5719.
75. Lonial S, Baz R, Swern AS, Weber D, Dimopoulos MA Neutropenia is a predictable and early event in affected patients with relapsed/refractory multiple myeloma treated with lenalidomide in combination with dexamethasone. Blood (ASH Annual Meeting Abstracts) 2009, 114. [Abstract 2879].
76. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366(19):1782-1791.
77. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012, 366(19):1759-1769.
78. McCarthy P, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 2012, 366(19):1770-1781.
79. Dimopoulos MA, Richardson PG, Brandenburg NA, Yu Z, Weber DM, Niesvizky R, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood blood-2011-08-373514; published ahead of print February 9, 2012, doi:10.1182/blood-2011-08-373514.
80. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. (eds). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, , based on November 2009 SEER data submission, posted to the SEER web site, 2010. http://seer.cancer.gov/csr/1975_2007/.
81. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007, 109(8):3489-3495.
82. Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009, 114(3):522-525.
83. Chng WJ, Mulligan G, Bryant B, Bergsagel L Survival of genetic subtypes of relapsed myeloma may be modulated by secondary events. Blood 2007, 109(8):3610-3611.
84. Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, IFM and MAG groups, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 2010, 24(3):623-628.
85. Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010, 24(10):1769-1778.
86. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010, 28(30):4630-4634.
87. Keith BD Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer 2008, 8:84.
88. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009, 27(30):5008-5014.
89. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011, 118(11):2970-2975.
90. Mateos M, Spencer A, Taylor K, Lonial S, De La Rubia J, Facon T, et al. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma. J Clin Oncol (ASCO Annual Meeting Abstracts) 2010, 28(15). (Suppl. Vol. I):[Abstract 8030].
91. Alsina M, Lonial S, Weber DM, Coutre SE, Kang BP, Glynos T, et al. PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM). J Clin Oncol (ASCO Annual Meeting Abstracts) 2010, 28(15). (Suppl. Vol. I):[Abstract TPS308].
92. Offidani M, Cavallo F, Polloni C, Liberati AM, Ballanti S, Pulini S, et al. Melphalan, thalidomide and prednisone (MPT) combined with oral panobinostat in patients with relapsed/refractory MM: a phase I-II study. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 3019].
93. Siegel DS, Weber DM, Mitsiades CS, Dimopoulos MA, Harousseau JL, Rizvi S, et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: a phase I study. J Clin Oncol (ASCO Annual Meeting Abstracts) 2009, 27(15). (Suppl. Vol. I):[Abstract 8586].
94. Richardson P, Weber D, Mitsiades CS, Dimopoulos MA, Harousseau J-L, Houp J, et al. A phase I study of vorinostat, lenalidomide, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: excellent tolerability and promising activity in a heavily pretreated population. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 1951].
95. Dimopoulos MA, Jagannath S, Yoon S-S, Siegel DS, Lonial S, Hajek R, et al. Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. Blood (ASH Annual Meeting Abstracts) 2011, 118. [Abstract 811].
96. Siegel DSd, Martin T, Wang M, Vij R, Jakubowiak AJ, Jagannath S, The MMRC, et al. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 985].
97. Stewart AK, Kaufman JL, Jakubowiak AJ, Jagannath S, Kukreti V, McDonagh KT, Multiple Myeloma Research Consortium (MMRC), et al. The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): updated results from the PX-171-004 study. J Clin Oncol (ASCO Annual Meeting Abstracts) 2011, 29(15). (Suppl. Vol. 1):[Abstract 8026].
98. Szymonifka J, Usmani SZ, Sexton R, Panozzo S, Nair BP, Waheed S, et al. Phase II study of carfilzomib (CFZ) in combination with current agents for relapsed and refractory multiple myeloma (RRMM). J Clin Oncol (ASCO Annual Meeting Abstracts) 2011, 29(15). (Suppl. Vol I):[Abstract 8028].
99. Niesvizky R, Bensinger W, Vallone M, Gutierrez A, Kunkel L PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): preliminary results. J Clin Oncol 2009, 27(15 Suppl.). [Abstract 8541].
100. Wang M, Bensinger W, Martin T, Alsina M, Siegel DSD, Gabrail NY, et al. Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). J Clin Oncol (ASCO Annual Meeting Abstracts) 2011, 29(15). (Suppl. Vol. I):[Abstract 8025].
101. Richardson PG, Moreau P, Jakubowiak AJ, Facon T, Jagannath S, Vij R, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: interim results of a phase 2 study. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 986].
102. Berdeja JG, Ailawadhi S, Niesvizky R, Wolf JL, Zildjian SH, O'Leary J, et al. Phase I study of lorvotuzumab mertansine (IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-Positive relapsed or relapsed/refractory mulitple myeloma - a preliminary safety and efficacy analysis of the combination. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 1934].
103. Raje NS, Hohl RJ, Faber EA, Richardson PGG, Forero-Torres A, Schiller GJ, et al. Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. J Clin Oncol (Annual Meeting Abstracts) 2011, 29(15). (Suppl. Vol. I):[Abstract 8012].
104. Belch A, Sharma A, Spencer A, Tarantolo S, Bahlis N, Doval D, et al. Results of an international, randomized phase II clinical trial of bortezomib mapatumumab (TRAIL-R1 agonist monoclonal antibody) for the treatment of relapsed/refractory multiple myeloma (MM). Haematologica (EHA Annual Meeting Abstracts) 2011, 96(Suppl. 2). [Abstract 1006].
105. Levact i.v.® (bendamustine hydrochloride) 2.5 mg/ml powder for concentrate for solution for infusion, August 2010 Accessed December 6, 2011. http://www.napponcology.com/_pdfs/Levact%20(bendamustine)%20SmPC.pdf.
106. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 2011, 155(5):632-634.
107. Lentzsch S, O'Sullivan A, Kennedy R, Gill N, Andreas C, Gardner D, et al. Combination of bendamustine, lenalidomide, and dexamethasone in patients with refractory or relapsed multiple myeloma is safe and highly effective: results of a phase I clinical trial. Blood (ASH Annual Meeting Abstracts) 2010, 116. [Abstract 989].
108. Fenk R, Michael M, Zohren F, Graef T, Czibere A, Bruns I, et al. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007, 48(12):2345-2351.
109. Ludwig H, Kasparu H, Gisslinger H, Thaler J, Greil R, Pour L, et al. Bortezomib-bendamustine-dexamethasone for treatment of relapsed/refractory myeloma. Haematologica (EHA Annual Meeting Abstracts) 2011, 96(Suppl. 2). [Abstract 0305].
110. Berenson R, Yellin O, Bessudo A, Boccia R, Noga S, Gravenor D, et al. An open-label, phase 1/2 trial of bendamustine plus bortezomib in patients with relapsed or refractory multiple myeloma. Haematologica (EHA Annual Meeting Abstracts) 2011, 96(Suppl. 2). [Abstract 0896].
111. Traer E, Deininger MW How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 2010, 9(Suppl. 1):S20-S26.